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Background: Difficulties in reliably diagnosing podoconiosis have severely limited the scale-up and uptake of
the World Health Organization–recommended morbidity management and disability prevention interventions
for affected people. We aimed to identify a set of clinical features that, combined into an algorithm, allow for
diagnosis of podoconiosis.
Methods: We identified 372 people with lymphoedema and administered a structured questionnaire on signs
and symptoms associated with podoconiosis and other potential causes of lymphoedema in northern Ethiopia.
All individuals were tested forWuchereria bancrofti–specific immunoglobulin G4 in the field using Wb123.
Results: Based on expert diagnosis, 344 (92.5%) of the 372 participants had podoconiosis. The rest had lym-
phoedema due to other aetiologies. The best-performing set of symptoms and signs was the presence of moss
on the lower legs and a family history of leg swelling, plus the absence of current or previous leprosy, plus the
absence of swelling in the groin, plus the absence of chronic illness (such as diabetes mellitus or heart or kid-
ney diseases). The overall sensitivity of the algorithm was 91% (95% confidence interval [CI] 87.6 to 94.4) and
specificity was 95% (95% CI 85.45 to 100).
Conclusions:We developed a clinical algorithm of clinical history and physical examination that could be used
in areas suspected or endemic for podoconiosis. Use of this algorithm should enable earlier identification of
podoconiosis cases and scale-up of interventions.
Keywords: diagnosis, clinical algorithm, clinical decision algorithms, Ethiopia, lymphoedema, podoconiosis
Introduction
Podoconiosis is a chronic inflammatory disease caused by long-
term contactwith irritantminerals in the soil.1 The disease causes
swelling of the lower leg, which interferes with the day-to-day
activities of affected individuals.2 The major signs and symp-
toms of the disease include lymphoedema of the lower legs
and acute dermatolymphangioadenitis (ADLA), which is charac-
terised by malaise, fever, chills, diffuse inflammation, swelling of
the limbs, lymphangitis, adenitis and eventually skin peeling.3 The
disease has major social and economic consequences through
stigma and loss of productivity.4,5 The disease can be prevented
by consistent use of footwear, foot hygiene and use of floor
coverings.2 The disease can be treated in its early stages
by using simple management of the lymphoedema-related
morbidity, which includes foot hygiene, skin care, wound care,
compression, exercises, elevation of the legs and treatment of
acute infections.3,6 Despite the formidable challenges the dis-
ease is presenting in endemic countries, there is no proven point-
of-care diagnostic method for the disease.7,8 The diagnosis of
the disease largely depends on clinical diagnosis and exclusion
of other potential causes of lymphoedema.9,10
Although clinical diagnosis of the disease has been used for
several years,11 there is no validated clinical algorithm for diag-
nosis of the disease.9,11 The diagnostic approach used to map
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
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Figure 1. Map of the study locations.
podoconiosis in Ethiopia, Cameroon and Rwanda was based on
excluding other potential causes of lymphoedema. The survey
conducted in Ethiopia used history and physical examination
to exclude other causes of lymphoedema, including systemic
disease, leprosy, onchocerciasis and hereditary causes of lym-
phoedema, and antigen-based immunochromatographic card
tests (ICTs) to exclude lymphatic filariasis (LF).9,12 In Cameroon,
clinical history, physical examination and certain disease-specific
tests described above were used to exclude common differential
diagnoses to reach the diagnosis of podoconiosis.13 All individuals
with lymphoedema included in the survey were tested for circu-
latingWuchereria bancrofti antigen and specific immunoglobulin
G4 (IgG4) in the field using, respectively, the Alere Filariasis Test
Strip (FTS) test14 and the SD BIOLINE LF IgG4 test (Wb123),15 in
addition to night thick blood films. DNA specific to W. bancrofti
was tested on night blood using the quantitative polymerase
chain reaction technique.13
Even though clinical diagnosis based on signs and symptoms is
frequently used, the way in which each of the clinical features of
podoconiosis predicts true diagnosis and the minimum require-
ments of signs and symptoms needed to reach the diagnosis
of podoconiosis have not been statistically validated.7 The accu-
rate identification of lymphoedema due to podoconiosis in areas
where other causes of lymphoedema, such as LF, are common
remains a challenge for primary healthcare workers.9 Although
there are point-of-care diagnostic tests for LF, which can easily
be implemented during large-scale surveys, these tests are costly
for routine practice and have low sensitivity in advanced cases.9
Early intervention among podoconiosis patients is important
in preventing the progression of lymphoedema.6 For early inter-
vention to be optimally effective, early detection is vital.7,16
As healthcare providers become progressively more involved
in examination, evaluation and early intervention programs,
increasing the accuracy of these examinations will be essential
to optimize these interventions. Evidence has shown that mor-
bidity management reduces disease severity and the frequency
of ADLA episodes, resulting in fewer days off work and an overall
improvement in quality of life.3,17 In addition, diagnosing podoco-
niosis in an individual provides an opportunity for counselling
family members (there is evidence of a genetic influence in sus-
ceptibility to the condition)18 and instigating primary prevention
strategies. Our study aimed to develop a diagnostic algorithm




The study was conducted in Ethiopia, within four woreda
(districts) in the Amhara region of northern Ethiopia (Figure 1) in
March 2017. These were selected to include areas of both high
and low prevalence of podoconiosis and areas where podoco-
niosis and LF are co-endemic. Zigem is an LF-endemic dis-
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albendazole and ivermectin was started in 2015. The district is
also of low endemicity for podoconiosis (1–5%).21,22 Yilma na
Dinsa is highly endemic for podoconiosis (>10%),20,21 but not for
LF.19,20 Debaytelat and Debremarkos are endemic for podoco-
niosis, with low prevalence (1–5%),21,22 and are non-endemic for
LF.19,20
Study population
Participantswere identified using convenience sampling. For each
of the four woreda visited, individuals with leg swelling were
mobilised to a local health centre in advance. Participants were
deemed eligible if they had lymphoedema of the lower leg(s).
Those who did not have lymphoedema of either of their lower
legs and individuals <15 y of age were excluded from the study.
The purpose andmethod of the study were explained in the local
language.
Data collection
For each participant, the diagnosis was established and docu-
mented by healthcare workers, all of them holding a bachelor’s
degree in nursing or health sciences and with ample experience
in the diagnosis of podoconiosis and lymphoedema. Their final
diagnosis was used as the reference standard.11,13 The health-
care workers used history, physical examination and Wb123 to
exclude other causes and arrive at the diagnosis of podoconio-
sis. The data collectors were provided with a half-day orienta-
tion on the procedure of data collection and the tools to be used.
Prospective data were collected using a standardised question-
naire that recorded demographic information, history and exam-
ination findings andWb123 test results. The variables included in
the index test questionnaire were selected on the basis that they
could easily be assessed by primary healthcare workers and were
relevant in establishing a diagnosis of podoconiosis. The Wb123
test was performed using the SD BIOLINE LF IgG4 test kit (Stan-
dard Diagnostic, Suwon, Korea) according to the manufacturer’s
instructions and results were read and recorded at both 30 min
and 24 h.13 Briefly, 10 μL of capillary blood was obtained from
each person by finger prick and applied to the sample application
pad of the Wb123. A single test was performed for each partic-
ipant by a trained laboratory technician. Before utilization of the
test, positive and negative quality control tests were conducted
as per the manufacturer’s instructions.15
Data analysis and algorithm construction
Descriptive analysis using a frequency table was conducted to
present the findings. Univariate logistic regression was done to
estimate the odds ratio (OR) to show potential association of the
signs and symptoms with podoconiosis. To develop a predictive
algorithm for diagnosis of podoconiosis, we developed a logistic
regression model for the probability that the ith individual has a
positive diagnosis, which we denote as pi for i=1, …, 372. Based
on the logistic regression model, our model for pi, which includes
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where xj denotes the jth explanatory variable of the 14 consid-
ered in this study.
Let β̂ j denote the maximum likelihood estimator for β j
and p̂i that for pi. Using the model in equation 1, we then
classify an individual as positive if the following statement
holds: ‘the probability, p, that p̂i exceeds a threshold R is
greater than Q’, or more formally p = Prob[ p̂i > R] > Q. Note
that this is mathematically equivalent to the statement p =
Prob[
∑14
j = 1 β̂ jx j > log{R/(1− R)}] > Q, hence to compute p we
can use the multivariate Gaussian distribution of the maximum
likelihood estimator for the β̂ j .
In order to identify the best subset of covariates xj that yields
the highest sensitivity and specificity, we proceed as follows.
We consider all possible combinations of covariates, totalling
214=16 384 logistic regression models, and for each of these we
use leave-one-out cross-validation to generate the probability S
for the ith individual excluded from the training set. Based on S,
the model then classifies each of the 372 individuals while opti-
mizing the parameters R and Q in order to maximize both the
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Table 2. Clinical signs and symptoms among people with lymphedema
Variable Categories n (%)
Type of swelling Unilateral 51 (13.7)
Bilateral 321 (86.3)
Does the swelling differ in size between the two legs? Yes 103 (32.2)
No 217 (67.8)
Is the swelling limited to below the knee? Yes 362 (98.9)
No 4 (1.1)
Where did the swelling start from? Lower leg 362 (97.6)
Elsewhere 9 (2.4)
Does the person have hydrocele? Yes 4 (2.1)
No 187 (97.9)
Did the person experience any acute attack in the past 6 months? Yes 266 (71.5)
No 106 (28.5)
Is the person a known leprosy patient now or in the past? Yes 7 (1.9)
No 363 (98.1)
Did the person live for more than 10 years in areas at least 1000 m altitude? Yes 349 (95.9)
No 15 (4.1)
Does the person have signs and symptoms of onchocerciasis? Yes 5 (1.3)
No 367 (98.6)
Is the person known to have diabetes mellitus, heart or kidney disease? Yes 19 (5.2)
No 348 (94.8)
Has the person had surgery below the hip? Yes 2 (0.5)
No 368 (99.4)
Is there swelling of the face or breast or other part of the body than the leg? Yes 9 (2.4)
No 362 (97.6)
Does the person have knob, bump or lump on the lower leg? Yes 38 (10.3)
No 330 (89.7)
Does the person have moss on the lower leg? Yes 202 (54.3)
No 170 (45.7)
Does the person have joint fixation of the lower leg? Yes 2 (0.5)
No 370 (99.5)
Shoe wearing habits Never 11 (3)
Sometimes 304 (82.6)
Always 53 (14.4)
Is there a family history of leg swelling? Yes 215 (58.1)
No 155 (41.9)
Wb123 test results at 30 min Negative 372 (100)
Wb123 test results at 24 h Negative 372 (100)
Expert diagnosis Podoconiosis 344 (92.5)
Other lymphoedema 28 (7.5)
All the computations were carried out using the R software
environment (version 3.6.3; R Foundation for Statistical Comput-
ing, Vienna, Austria).23
Ethical considerations
Written informed consent was obtained for all participants. If a
selected individualwas between 16 and 18 y of age, verbal assent
and permission were obtained from the study participant and
a legal guardian, respectively. This included consent to undergo
Wb123 testing. For those who could not write, informed consent
was provided through a fingerprint.
All enrolled participants were given an education session
regarding the diagnosis and management of podoconiosis,
including a demonstration of how towash their feet and legs reg-
ularly with soap and water.
Results
A total of 372 participants with lymphoedema of the lower leg
were included in the study. Most of them (252 [67.7%]) were
fromYilma naDinsa, 96 (25.8%)were fromZigem, 15 (4.1%)were
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Table 3. Univariate logistic regression analysis
Lymphedema cause
Variable Podoconiosis Other Unadjusted OR (95% CI) p-Value
Sex (n=372)
Male 180 (52.3) 11 (39.3) 1.7 (0.8 to 3.7) 0.19
Female 164 (47.7) 17 (60.7) 1.0
Type of swelling (n=372)
Unilateral 44 (12.8) 7 (25.0) 1.0
Bilateral 300 (87.2) 21 (75.0) 0.4 (0.2 to 1.1) 0.08
Dose the person have swelling in the groin area (n=321)? 1.0
Yes 84 (28.0) 2 (9.5) 3.7 (0.84 to 16.21) 0.08
No 216 (72.0) 19 (90.5) 1.0
Does the swelling differ in size between the two legs?a
Yes 93 (31.1) 10 (47.6) 0.095b
No 206 (68.9) 11 (52.4)
Is the swelling limited to below the knee? (n=366)
Yes 335 (98.8) 27 (100) 0.5 (0.2 to 1.2) 0.12
No 4 (1.2) 0 (0.0) 1.0
Where did the swelling start from? (n=371)
Lower leg 339 (98.8) 23 (82.1) 1.0
Elsewhere 4 (1.2) 5 (17.9) 0.05 (0.01 to 0.22) <0.001
Did the person experience an acute attack in the past 6 months? (n=372)
Yes 253 (73.5) 13 (46.4) 3.2 (1.4 to 7.0) 0.003
No 91 (26.5) 15 (53.6) 1.0
Is the person experiencing an acute attack during the interview? (n=370)
Yes 5 (1.5) 1 (3.6) 0.4 (0.04 to 3.55) 0.411
No 337 (98.5) 27 (96.4) 1.0
Is the person a known leprosy patient now or in the past? (n=370)
Yes 3 (0.9) 4 (14.3) 0.05 (0.01 to 0.25) <0.001
No 339 (99.1) 24 (85.7) 1.0
Has the person lived for >10 y at areas >1000 m altitude? (n=364)
Yes 323 (96.1) 26 (92.9) 1.91 (0.41 to 8.93) 0.41
No 13 (3.9) 2 (7.1) 1.0
Does the person have signs or symptoms of onchocerciasis? (n=372)a 0.675b
Yes 5 (1.5) 0 (0.0)
No 339 (98.5) 28 (100)
Is the person known to have diabetes mellitus, heart or kidney disease? (n=367)
Yes 17 (5.0) 2 (7.1) 0.67 (0.15 to 3.13) 0.627
No 322 (95.0) 26 (92.9) 1.0
Is there a history of surgery below the hip? (n=370)a 0.854b
Yes 2 (0.6) 0 (0.0)
No 340 (99.4) 28 (100)
Is there swelling on any other part of the body? (n=371)
Yes 6 (1.7) 3 (10.7) 0.15 (0.04 to 0.63) 0.01
No 337 (98.3) 25 (89.3) 1.0
Does the person have a knob, bump or lump on the lower leg? (n=368)£ 0.047b
Yes 38 (11.1) 0 (0.0)
No 303 (88.9) 27(100)
Does the person have moss on the lower leg? (n=372) χ2=33.65 <0.001c
Yes 202 (58.7) 0 (0.0)
No 142 (41.3) 28 (100)
Does the person have joint fixation of the lower leg? (n=372) 0.885b
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Table 3. continued
Lymphedema cause
Variable Podoconiosis Other Unadjusted OR (95% CI) p-Value
No 342 (99.4) 28(100)
Shoe wearing habits (n=368)
Never 10 (2.9) 1 (3.7) 0.82 (0.08 to 8.10) 0.862
Sometimes 282 (82.7) 22 (81.5) 1.05 (0.35 to 3.17) 0.936
Always 49 (14.4) 4 (14.8) 1.0
Family history of leg swelling?
Yes 210 (61.4) 5 (17.9) 7.32 (2.72 to 19.72) <0.001
No 132 (38.6) 23 (82.1) 1.0
Duration of swelling
>1 y 343 (99.7) 23 (85.2) 59.6 (6.4 to 555.6) <0.001
≤1 y 1 (0.3) 4 (14.8)
aBecause of zero values we were unable to fit a logistic regression model.
bFisher’s exact test.
cχ2 with continuity correction.
Table 4. Performance of individual signs and symptoms









Bilateral swelling 87.2 25 93.5 13.7 82.5 
Asymmetrical swelling  31.1 52.4 90.3 5.1 32.5 
No swelling in the groin areas 72 9.5 91.9 2.3 67.9 
Swelling limited to below the knee 98.8 0 92.5 0 91.5 
Swelling started from the lower leg  98.8 17.9 93.6 55.6 92.7 
Experienced acute attack in the past 6 months 73.5 53.6 95.1 14.1 72 
Experiencing acute attack during the interview 1.5 96.4 83.3 7.4 8.6 
No history of leprosy  99.1 14.3 93.4 57.1 92.7 
Lived for more than 10 years at ≥1000 m altitude? 96.1 7.1 92.6 13.3 89.3 
No sign or symptom of onchocerciasis 98.5 0 92.4 0 91.1 
No known diabetes mellitus, heart or kidney disease 95 7.1 92.5 10.5 88.3 
No history of surgery below the hip 99.4 0 92.4 0 91.9 
No swelling on other parts of the body 98.3 10.7 93.1 33.3 91.6 
Presence of knob/bump, lump on lower leg 11.1 100 100 8.2 17.7 
Presence of moss on lower leg 58.7 100 100 16.5 61.8 
Presence of joint fixation on lower leg 0.6 100 100 7.6 8.1 
Family history of leg swelling 61.4 82.1 97.7 14.8 63 
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Table 5. Point estimates and 95% CIs for the predictors from the model having the highest sensitivity and specificity
Variables Adjusted OR (95% CI)
Does the person have moss on the lower leg? (n=372)a
Yes
No
Is the person a known leprosy patient now or in the past? (n=370)
Yes 1.0
No 19.42 (0.87 to 434.74)
Does the person have swelling in the groin area? (n=321)
Yes 0.11 (0.02 to 0.64)
No 1.0
Is the person known to have diabetes mellitus, heart or kidney disease? (n=367)
Yes 1.0
No 17.96 (1.58 to 204.02)
Family history of leg swelling? (n=370)
Yes 1.0
No 0.038 (0.01 to 0.22)
aThis model also includes moss, whose OR cannot be reliably estimated due to the absence of patients for which with no moss and also tested
negative for podoconiosis.
Fifty-one percent were male, 80% were from urban areas, 32%
were able to read and write and 11% had attended formal edu-
cation (Table 1).
Table 2 shows the signs and symptoms recorded among peo-
ple with lymphoedema. The majority of the cases had bilat-
eral (321 [86.3%]), symmetrical (217 [67.8%]) and below-the-
knee (362 [98.9%]) swelling, which started from the lower leg
(362 [97.6%]), and slightly more than half (202 [54.3%]) had
mossy changes. Very few people with hydrocele were identified
(4 [2.1%]). For all 372 participants, the results of the Wb123 test
were negative at both the 30-min and 24-h readings. Based on
expert diagnosis, 344 of 372 participants (92.5%) were podoco-
niosis cases and the remaining 28 (7.5%) were due to lym-
phoedema of other causes.
Table 3 shows the results of univariate regression analysis.
Of the 16 variables included, only 6 variables were found to be
significant. Swelling that started from the lower leg, swelling of
≥1 y duration, experiencing an acute attack in the past 6 months
and family history of lower leg swelling increased the odds of
being a podoconiosis patient. However, a history of leprosy and
swelling of other parts of the body were associated with a lower
risk of being a podoconiosis patient. In addition, the presence
of moss and the presence of a knob, bump or lump on the
lower leg were significantly associated with podoconiosis in a
χ2 test.
The performance of the individual signs and symptoms is
described in Table 4. In multivariate logistic regression, the best
predictive model contained five variables (Table 5). People with
lymphoedema and no history of leprosy had higher odds of
podoconiosis (OR 19.42 [95% confidence interval {CI} 0.87 to
434.74]) than those with such a history. People with swelling in
the groin area had lower odds of podoconiosis compared with
those without (OR 0.11 [95% CI 0.02 to 0.64]). People without
known chronic illness such as diabetes mellitus or heart or kidney
disease had higher odds of podoconiosis compared with those
with such diseases (OR 17.96 [95% CI 1.58 to 204.02]). People
without a family history of leg swelling had lower odds of podoco-
niosis than those with a family history (OR 0.038 [95% CI 0.01 to
0.22]).
As depicted in Figure 2, the best performing set of symptoms
and signs was the presence of moss on the lower legs and a fam-
ily history of leg swelling, plus the absence of current or previous
leprosy, plus the absence of swelling in the groin, plus the absence
of chronic illness (such as diabetesmellitus or heart or kidney dis-
eases) with the order indicated in Figure 2. The overall sensitivity
of the algorithm was 91% (95% CI 87.6 to 94.4) and specificity
was 95% (95% CI 85.45 to 100). The positive predictive value and
negative predictive value were 99.6% (95% CI 98.8 to 100) and
41.2% (95% CI 28.54 to 57.82), respectively.
Discussion
The clinical, social and economic burden caused by podoco-
niosis is enormous in endemic countries.4,24–27 Recognition of
this has led us to develop a simple clinical algorithm to help
primary healthcare workers accurately diagnose podoconiosis.
We found that the presence of moss on the lower legs and a
family history of leg swelling, the absence of current or previ-
ous leprosy, the absence of swelling in the groin and the absence
of chorionic illness (such as diabetes mellitus or heart or kid-
ney diseases) can identify people with lymphoedema with a high
probability of podoconiosis. The algorithm has a favourable per-
formance in identifying podoconiosis cases across settings of
varying endemicity. We believe this algorithm and the screening
questions are acceptable for practitioners in endemic countries
because they are signs and symptoms classically associated with
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Figure 2. Algorithm for the diagnosis of podoconiosis in persons with lower leg lymphoedema.
Misdiagnosis and delayed diagnosis of podoconiosis con-
tinue to be a challenge in endemic countries. This means that
patients with podoconiosis are denied the treatment and care
they deserve, contributing to significant morbidity, reduced qual-
ity of life and reduced productivity.29 In the absence of a rapid,
reliable and effective point-of-care diagnosis, the need for a sim-
ple clinical algorithm to screen people with lymphoedema that
differentiates people with and without podoconiosis is impor-
tant.7 The algorithm presented here is an efficient method for
diagnosing podoconiosis, comprising five simple questions eas-
ily assessed by primary healthcare workers. The algorithm iden-
tifies patients with lymphoedema of the lower limbs in whom a
diagnosis of podoconiosis is likely and who should therefore be
managedas such. Thiswill allow simple interventions to be imple-
mented in the primary healthcare setting and has the potential
to significantly reduce morbidity and improve quality of life. As
many patients with podoconiosis live in remote areas andmay be
unable to travel to a secondary healthcare centre, the algorithm
may allow them to be diagnosed and managed in their local
community.25 For those patients in whom a diagnosis is deemed
unlikely or inconclusive according to the algorithm, the health-
care worker might refer them to the next level of the healthcare
system to perform further detailed assessment and appropriate
investigation.
The algorithm, which can be used by healthcare workers with
minimal training, correctly identified 91% of people with podoco-
niosis and 95% of those without podoconiosis. Of the total 372
participants included in our study, the majority (344 [92.5%])
were podoconiosis cases and only 28 people with lymphoedema
due to other causes were identified. Although we included one
LF-endemic district, none of the people with lymphoedema had
a positive Wb123 test. Nonetheless, it is worth mentioning that
previous LF-specific nationwide studies and subsequent geosta-
tistical models have shown that LF is focal and its transmis-
sion intensity is low in Ethiopia.9,30,31 We thus expect that the
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clinical algorithm in areas highly endemic for LF may increase its
performance by increasing its specificity. Therefore it is likely that
any particular algorithmwill be site specific and it will probably be
necessary to improve the performance by including different dif-
ferential diagnoses for different geographical areas. For example,
one of the questions concerns a history of leprosy, which would
only be valid in areas where leprosy is endemic. However, we
believe that the principles underlying this approach to the diag-
nosis of podoconiosis could be appliedmore widely. Further stud-
ies in areas with different epidemiological patterns and a variable
presence of confounding diseases are needed to see if this is the
case.
Our study has several strengths, especially the simplicity of
the signs and symptoms included in our clinical algorithm, which
allow it to be implemented by primary healthcare workers with
minimal training. Also, we included districts with a range of
epidemiological profiles of podoconiosis and other potential
causes of lymphoedema. Nevertheless, there are some limi-
tations to our work. First, we included signs and symptoms
that are closely associated with podoconiosis and major tropi-
cal lymphoedemas. However, there are several other causes of
lymphoedema associated with different clinical features.32 It is
possible that the addition of one or more pertinent additional
question that was not included in our study could increase the
performance of the algorithm. Second, we used clinical diag-
nosis by healthcare workers as the gold standard for diagnosis
of podoconiosis. Podoconiosis is a clinical diagnosis and there
is no point-of-care diagnostic test. However, to support clinical
decision-making by experienced healthcare providers we per-
formedWb123 tests to potentially exclude LF. Limitations related
to the Wb123 test should also be put into context. First, the
Wb123 test cannot distinguish current active infection from past
infection in individuals from endemic areas.15 This limitationmay
not be of particular importance in our case since identification
of individuals with current or previous disease would help in
excluding cases due to LF. Second, the Wb123 test has a lower
specificity and sensitivity compared with the FTS. Although the
studied areas are generally low LF prevalence areas, we might
have missed LF-positive cases with lymphoedema. Therefore, for
future studies we suggest the use of FTS or the use of both tests
based on the epidemiology of other confounding diseases.15,33
The majority of individuals included in the study had a diag-
nosis of podoconiosis and only a small number of patients had
other types of lymphoedema. In view of this, we were unable to
separate the data into training and test groups, as this would
have left too few patients with non-podoconiosis-related lym-
phoedema in each group. As a result, we have not yet been able
to fully validate the algorithm.We are planning to do this in future
work and include clinical data from other endemic regions to
further assess its accuracy. Ideally the algorithm proposed here
should be prospectively evaluated in multiple countries and geo-
graphic regions, as our study was conducted in just one region of
Ethiopia.
Conclusions
Early diagnosis and timelymorbiditymanagement of podoconio-
sis require the development of a rapid, accurate, point-of-care
diagnostic test. In the absence of such a test, a standardized
algorithmusing signs and symptoms, such as the onewe propose
here, will help in early diagnosis and treatment of podoconiosis,
reducing the suffering of people with podoconiosis and improving
their quality of life.
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